Curia nets contract for cannabinoid candidate and taps a new president of manufacturing
The CDMO Curia, fresh off an expansion a year ago, is scaling up manufacturing for a candidate from an Australian biotech.
Incannex Healthcare, a biotech centered on producing cannabinoid-based medicines and psychedelic therapies, is using Curia Global to further develop and manufacture a GMP-grade inhaled drug product for the treatment of concussion and traumatic brain injury originally developed by the biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.